Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Retinal Consultants of Arizona
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Retinal Consultants of Arizona
ClinicalTrials.gov Identifier:
NCT01673191
First received: August 22, 2012
Last updated: March 19, 2014
Last verified: March 2014

August 22, 2012
March 19, 2014
November 2012
August 2014   (final data collection date for primary outcome measure)
Percentage of patients with significant decrease in OCT (e.g., 50-100 µm) following treatment with OZURDEX®. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01673191 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

There is a need to find an effective therapy for diabetic patients who develop macular edema after cataract surgery. The objective of this study is to assess the safety and efficacy of the OZURDEX® intraocular implant in patients with diabetes mellitus, who develop macular edema after cataract surgery.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Macular Edema After Cataract Surgery in Patients With Diabetes Mellitus
  • Drug: Dexamethasone intravitreal implant
    Other Name: OZURDEX
  • Drug: Steroid plus NSAID eye drop combination therapy
    Other Name: Acular LS and Pred Forte
  • Experimental: OZURDEX intraocular implant
    OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
    Intervention: Drug: Dexamethasone intravitreal implant
  • Active Comparator: Steroid plus NSAID eye drop combination therapy
    NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
    Intervention: Drug: Steroid plus NSAID eye drop combination therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2014
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has diagnosis of Diabetes Mellitus, Type I or II.
  • Patient has experienced the development of macular edema following cataract surgery in at least one eye.
  • Patient has had cataract surgery within 90 days prior to the screening visit.

Exclusion Criteria:

  • Patient has other significant ocular disease in study eye, including glaucoma.
  • Patient has any active infection in the study eye.
  • Patient has uncontrolled systemic illness (i.e., uncontrolled blood pressure, uncontrolled diabetes mellitus).
  • Patient has experienced a significant increase in intraocular pressure following a prior treatment with topical or intravitreal steroidal medication.
  • Patient has received the OZURDEX® implant before in the study eye.
Both
18 Years and older
No
United States
 
NCT01673191
RCA2012
No
Retinal Consultants of Arizona
Retinal Consultants of Arizona
Allergan
Principal Investigator: Pravin U Dugel, MD Retinal Consultants of Arizona
Retinal Consultants of Arizona
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP